Today, Ocumetics has entered the history books. Nearly two decades of relentless innovation, bold ambition, and unwavering belief have led to this defining moment: the first-in-human implantation of the Ocumetics Lens.
What many once thought impossible is now reality. This achievement is not the work of one person or one idea, but the result of years of persistence by an extraordinary team of scientists, engineers, clinical advisors, and partners who refused to let go of a vision to transform human sight.
This is more than a milestone; it is a turning point for ophthalmology and for millions of people worldwide who are waiting for new solutions. And while we celebrate this historic success, we know our mission is far from complete. With more determination than ever, we move forward to deliver the Ocumetics Lens to patients everywhere and reshape the future of vision.
Best regards
Dean Burns
President, CEO and Director
Ocumetics Technology
Calgary, Alberta – TheNewswire – December 9, 2025 – Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, is pleased to announce that Medicel AG (“Medicel”), a global leader in ophthalmic device delivery systems, has further modified its lens delivery technology in response to
Dear Investors, I have received several inquiries about our October 8th press release. It marks an exciting and historic milestone for Ocumetics. The patients selected for our first clinical group entered the study with very poor functional vision due to cataracts and were struggling to see clearly at distance. One month following cataract surgery and
Ocumetics Director and CEO, Dean Burns covers important updates on our first-in-human (FIH) study and what lies ahead. Topics include: Encouraging outcomes from initial surgeries Next steps to complete the FIH study Live Q&A session with Dean Burns https://youtu.be/rWQnOaq6sVE
